Roland Peter S, Kreisler Leslie S, Reese Bradley, Anon Jack B, Lanier Brent, Conroy Peter J, Wall G Michael, Dupre Sheryl J, Potts Susan, Hogg Gail, Stroman David W, McLean Celeste
Department of Otolaryngology, University of Texas Southwestern Medical Center, Dallas 75390-9035, USA.
Pediatrics. 2004 Jan;113(1 Pt 1):e40-6. doi: 10.1542/peds.113.1.e40.
To determine the efficacy and safety of topical ciprofloxacin/dexamethasone otic suspension compared with ofloxacin otic solution in the treatment of acute otitis media with otorrhea through tympanostomy tubes (AOMT) in pediatric patients.
This multicenter, prospective, randomized, observer-masked, parallel-group study was conducted at 39 sites in 599 children aged >or=6 months to 12 years with an AOMT episode of <or=3 weeks' duration. The mean age of patients was 2.5 years (standard deviation: 2.37 years). Patients received either ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension 4 drops twice daily for 7 days or ofloxacin 0.3% otic solution 5 drops twice daily for 10 days. Clinical signs and symptoms of AOMT were evaluated at clinic visits on days 1 (baseline), 3 (on therapy), 11 (end of therapy), and 18 (test of cure). A patient diary was used to measure time to cessation of otorrhea. Principal pretherapy pathogens included Streptococcus pneumoniae (16.8%), Staphylococcus aureus (13.0%), Pseudomonas aeruginosa (12.7%), Haemophilus influenzae (12.4%), S epidermidis (10.2%), and Moraxella catarrhalis (4.1%).
Ciprofloxacin/dexamethasone is superior to ofloxacin for clinical cure (90% vs 78%) and microbiologic success (92% vs 81.8%) at the test-of-cure visit, produces fewer treatment failures (4.4% vs 14.1%), and results in a shorter median time to cessation of otorrhea (4 days vs 6 days). Ciprofloxacin/dexamethasone treatment is also superior to improvement in clinical response by visit, absence of otorrhea by visit, and reduction of otorrhea volume by visit. Both topical otic preparations are safe and well tolerated in pediatric patients. No change in speech recognition threshold or decrease in hearing from baseline, based on audiometric testing, was noted with either regimen.
Topical ciprofloxacin/dexamethasone treatment is superior to topical ofloxacin in the treatment of AOMT.
比较环丙沙星/地塞米松耳用混悬液与氧氟沙星耳用溶液治疗小儿鼓膜置管型急性中耳炎伴耳漏(AOMT)的疗效和安全性。
本多中心、前瞻性、随机、观察者盲法、平行组研究在39个地点对599名年龄≥6个月至12岁、AOMT病程≤3周的儿童进行。患者平均年龄为2.5岁(标准差:2.37岁)。患者接受0.3%环丙沙星/0.1%地塞米松耳用混悬液,每日两次,每次4滴,共7天;或0.3%氧氟沙星耳用溶液,每日两次,每次5滴,共10天。在第1天(基线)、第3天(治疗中)、第11天(治疗结束)和第18天(治愈检测)的门诊就诊时评估AOMT的临床体征和症状。使用患者日记来测量耳漏停止时间。治疗前主要病原体包括肺炎链球菌(16.8%)、金黄色葡萄球菌(13.0%)、铜绿假单胞菌(12.7%)、流感嗜血杆菌(12.4%)、表皮葡萄球菌(10.2%)和卡他莫拉菌(4.1%)。
在治愈检测就诊时,环丙沙星/地塞米松在临床治愈率(90%对78%)和微生物学成功率(92%对81.8%)方面优于氧氟沙星,治疗失败更少(4.4%对14.1%),耳漏停止的中位时间更短(4天对6天)。环丙沙星/地塞米松治疗在每次就诊时的临床反应改善、每次就诊时无耳漏以及每次就诊时耳漏量减少方面也更优。两种耳用局部制剂在小儿患者中均安全且耐受性良好。两种治疗方案在听力测试中均未发现言语识别阈值变化或听力较基线下降。
局部应用环丙沙星/地塞米松治疗AOMT优于局部应用氧氟沙星。